Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Sanofi Consumer Healthcare India Current Ratio?
Sanofi Consumer Healthcare IndiaBOM:544250 -0.08%21 Current Ratio is 2.03 as of Jun. 2026, which is 26% below its 10-year median of 2.75. GuruFocus rates BOM:544250 with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 1,000 Drug Manufacturers companies, Sanofi Consumer Healthcare India ranks better than 51.8% on this metric.
Sanofi Consumer Healthcare India (BOM:544250) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Sanofi Consumer Healthcare India Current Ratio Related Terms
Sanofi Consumer Healthcare India Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi Consumer Healthcare India Current Ratio Chart
BOM:544250 vs LLY, JNJ, ABBV: Current Ratio Comparison
For the Drug Manufacturers - General subindustry, Sanofi Consumer Healthcare India's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Consumer Healthcare India Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi Consumer Healthcare India's Current Ratio distribution charts can be found below:
* The bar in red indicates where Sanofi Consumer Healthcare India's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi Consumer Healthcare India (BOM:544250) has a Current Ratio of 2.03 as of Jun. 2026. This is 26% below median its historical median of 2.75. Over the past decade, Sanofi Consumer Healthcare India's Current Ratio has ranged from 2.03 to 3.85. According to the industry distribution chart, Sanofi Consumer Healthcare India ranks #482 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 48.2%.
Is Sanofi Consumer Healthcare India's Current Ratio too high?
Sanofi Consumer Healthcare India's current Current Ratio of 2.03 is 26% below median its 10-year median of 2.75. Over the past 10 years, this metric has ranged from a low of 2.03 to a high of 3.85. The Drug Manufacturers industry median Current Ratio is 1.98. Sanofi Consumer Healthcare India's value of 2.03 is 2.8% above this industry median. Based on the distribution chart, Sanofi Consumer Healthcare India ranks #482 out of 1000 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's Current Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi Consumer Healthcare India ranks #482 out of 1000 companies for Current Ratio. This puts Sanofi Consumer Healthcare India in the upper half of its industry. The industry median Current Ratio is 1.98. Sanofi Consumer Healthcare India's value of 2.03 is 2.8% above this benchmark. Historically, Sanofi Consumer Healthcare India's own Current Ratio has ranged from 2.03 to 3.85 over the past decade. While the company's 10-year median is 2.75 vs. the industry median of 1.98, Sanofi Consumer Healthcare India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.98, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi Consumer Healthcare India's current Current Ratio of 2.03 is 2.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi Consumer Healthcare India's current Current Ratio is 2.03, which is 26% below median its own 10-year median of 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (BOM:544250) has a current Current Ratio of 2.03. The current Current Ratio is 2.03, which is 26% below median its 10-year median of 2.75 and 2.8% above the Drug Manufacturers industry median of 1.98. Sanofi Consumer Healthcare India's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (BOM:544250), the current Current Ratio is 2.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
21GF Score
Get the complete analysis for BOM:544250
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544250 has been successfully added to your 
